Neuro-Opiomelsp. z o.o.
Other research and experimental development on natural sciences and engineering
Overview
Neuro-Opiomel is a Polish biotechnology company providing laboratory and research services to pharmaceutical and biotechnology companies and research institutions. Its services include peptide synthesis and characterisation, physicochemical and structural analyses, purity and stability testing, and analytical method development and validation; the company is undergoing GMP certification for quality control and batch release of medicinal products.
Financials
Revenue history (in k)
Filing timeliness
2 of 6 financial statements were filed late (the longest delay 94 days for 2021).
- 202510/07/2026
- 202428/07/2025
- 202305/07/2024
- 202229/06/2023
- 202117/10/2022
- 202002/07/2021
The statements for 2020 report only zeros (no activity).
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Offer
- Peptide synthesis
- Peptide characterization
- Physicochemical analyses
- Structural analyses
- Active substance identification
- Stability testing
- Analytical method validation
Authorized Representatives
Manner of representation
In the case of a one-person management board, the sole member of the management board is authorised to make declarations of will on behalf of the company independently. If the management board is multi-member, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations of will on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Aleksandra Misicka Kęsikage 76 | 25 | $337.66 | 17.7305% |
Barbara Elżbieta Przewłockaage 84 | 25 | $337.66 | 17.7305% |
Andrzej Reszkaage 52 | 51 | $688.82 | 36.1702% |
Beata Wileńskaage 44 | 20 | $270.12 | 14.1844% |
Ewa Barbara Witkowska | 20 | $270.12 | 14.1844% |
Beneficial owners
| Person | Rights |
|---|---|
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Sep 22, 2021 | Aid for research and development projects: industrial research | $4.7M$4,659,338 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Sep 22, 2021 | Aid for research and development projects: experimental development | $495.3K$495,267 | Dyrektor Narodowego Centrum Badań i Rozwoju |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Opessp. z o.o. | $56,182.11 | opes.com.pl | ||
| Medapp Clinical Researchsp. z o.o. | $55,499.75 | medappclinicalresearch.pl | ||
| Receptonsp. z o.o. | $50,611.05 | receptonbiotech.com | ||
| ETA Innovations Research Hub Not for Profitsp. z o.o. | $49,920.43 | etainnovations.com | ||
| Orphinic ScientificS.A. | $42,972.42 | orphinic.com | ||
| Stenocoatsp. z o.o. | $36,665.21 | stenocoat.com | ||
| Pioligonsp. z o.o. | $29,597.16 | pioligon.pl | ||
| Spektrinosp. z o.o. | $21,528.32 | spektrino.com | ||
| Scilosp. z o.o. | $12,634.81 | scilo.eu | ||
| Microbiota Medsp. z o.o. | $7,423.69 | microbiota-med.com |
FAQ
Last updated: 2026-07-16